- About Breast Cancer
- Community Impact
- Get Involved
Save the date! Komen New England 2nd Annual Breast Cancer Symposium
March 23, 2018
Recap: Komen New England 1st Annual Breast Cancer Symposium
From Awareness to Action: Reducing Breast Cancer Mortality
In 2016, Susan G. Komen® announced our bold goal: by 2026, reduce current rates of breast cancer mortality in the U.S. by 50%. On March 31, 2017, Komen New England hosted the 1st Annual Breast Cancer Symposium. Attendees heard from distinguished keynote speaker Dr. Eric Winer, Komen Scholars, researchers and leaders. Attendees learned about cutting-edge strategies to both ensure high-quality breast cancer care for all our neighbors as well as foster research to find the causes and cures.
Topics included were:
- New approaches to metastatic breast cancer research: immunotherapy and crowd sourcing
- Creating health equity for minority breast cancer patients
- Improving minority participation in clinical trials
- The role of patient navigation in addressing breast cancer disparities
To view the video recording of each session, click here.
To view photos from the event, click here.
Eric P. Winer, M.D., is Professor of Medicine at Harvard Medical School and Chief, Division of Women’s Cancers and the Thompson Chair in Breast Cancer Research at Dana-Farber Cancer Institute. He is the 2009 recipient of the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School.
Dr. Winer has devoted his professional career to the treatment of individuals with breast cancer and breast cancer research. He, personally, has designed and led phase I, II, and III clinical trials. He has collaborated closely throughout his career with psychosocial researchers, health services researchers, and both basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer and minimizing suffering and morbidity from the disease. Dr. Winer’s research interests also include quality of life, psychosocial aspects of cancer, medical decision making, and doctor-patient communication. His Komen-funded research is focused on reducing racial disparities in breast cancer and is also looking at preoperative therapies for patients with HER+ breast cancer.
Ian Krop is the Chief of Breast Medical Oncology and the Director of Clinical Research for the Breast Oncology Program at Dana-Farber Cancer Institute. He is also an Associate Professor of Medicine at Harvard Medical School.
Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugate trastuzumab emtainsine (T-DM1). Dr. Krop is a member of the National Cancer Institute’s Breast Cancer Steering Committee, the Eastern Cooperative Oncology Group Data Monitoring Committee, and is co-chair of the HER2-working group of the Translational Breast Cancer Research Consortium.
Nikhil Wagle is an Assistant Professor of Medicine at Harvard Medical School, a medical oncologist at Dana-Farber Cancer Institute, and an associate member of the Broad Institute of MIT and Harvard. He is the Deputy Director of the Center for Cancer Precision Medicine at Dana-Farber Cancer Institute.
Dr. Wagle leads The Metastatic Breast Cancer Project (mbcproject.org), a nationwide direct-to-patient research initiative that engages patients with advanced breast cancer through social media and seeks to empower them to accelerate cancer research through sharing their samples and clinical information. The project’s outreach program, developed in collaboration with advocacy organizations and patients, serves to connect thousands of patients around the U.S. with metastatic breast cancer research, allowing them to participate regardless of where they live.
Erica Warner is an Instructor in the Department Medicine at Harvard Medical School and an Assistant Investigator at Massachusetts General Hospital where she conducts epidemiological research on cancer, with a focus on breast cancer. She is also Research Associate at Harvard T.H. Chan School of Public Health in the Department of Epidemiology. She is a member of the Dana-Farber Harvard Cancer Center in the Cancer Epidemiology and Breast Cancer programs.
Dr. Warner studies how lifestyle, behavioral, and genetic factors affect risk of cancer, particularly aggressive molecular subtypes, as well as factors that lead to more deadly forms cancer and higher risk of cancer mortality in racial/ethnic minority populations. Dr. Warner has collaborated with the Alliance for Clinical Trials in Oncology, the Nurses’ Health Studies and the Black Women’s Health Study.
Melissa Bishop-Murphy is Senior Director of National Government Relations and Multicultural Affairs for Pfizer, Inc. She is responsible for regulatory, legislative and public policy matters at Pfizer, Inc. Ms. Bishop-Murphy has extensive work experience throughout the Southeast, Washington, DC and Delaware. Prior to her position as Senior Director, she was Director/Team Leader of government relations for the Southeast region of the United States that included the District of Columbia, Virginia, Florida, South and North Carolina, Alabama, Tennessee, and Georgia. She currently lobbies in Georgia, South Carolina, and North Carolina.
Additionally, Ms. Bishop-Murphy works nationally to build multicultural coalitions to advocate for greater access to healthcare and pharmaceuticals. She co-chairs Pfizer’s Multicultural Center of Excellence. She also serves as chair of the National Hispanic Nurses’ Association Corporate Roundtable. Ms. Bishop-Murphy previously served as Chair of the Corporate Roundtable of the National Black Caucus of State Legislators. She is also a member of the National Hispanic Caucus of State Legislators Business Roundtable.